MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis

BACKGROUND: Accurate diagnosis of tumefactive demyelinating lesions is clinically important to avoid unnecessary invasive biopsy or inappropriate treatment. PURPOSE: We aimed to evaluate conventional and advanced MR imaging findings of tumefactive demyelinating lesions and determine the diagnostic performance of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor. DATA SOURCES: A systematic search of Ovid MEDLINE and EMBASE up to December 6, 2017, was conducted. STUDY SELECTION: Original articles describing MR imaging findings in patients with tumefactive demyelinating lesions were selected. DATA ANALYSIS: The pooled incidences of conventional MR imaging findings of tumefactive demyelinating lesions were obtained with the DerSimonian and Liard random-effects model. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were obtained using the bivariate random-effects model. DATA SYNTHESIS: Nineteen eligible studies with 476 patients with tumefactive demyelinating lesions were included. The pooled incidence of open ring or incomplete rim enhancement was 35% (95% CI, 24%–47%), which was significantly higher than the incidence of closed ring or complete rim enhancement (18% [95% CI, 11%–29%]; P = .0281). The pooled incidences of T2 hypointense rim, absent or mild mass effect, and absent or mild perilesional edema were 48%, 67%, and 57%, respectively. On advanced MR imaging, tumefactive demyelinating lesions showed a high apparent diffusion coefficient, peripheral restricted diffusion, and low cerebral blood volume. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were 89% (95% CI, 82%–93%) and 94% (95% CI, 89%–97%), respectively. LIMITATIONS: Seventeen of 19 studies were retrospective studies. CONCLUSIONS: Conventional MR imaging findings may help differentiate tumefactive demyelinating lesions from primary brain tumor, though further study is needed to determine the added value of advanced MR imaging.

[1]  R. Jain,et al.  Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features , 2017, Clinical Neurology and Neurosurgery.

[2]  V. Meca-Lallana,et al.  Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature. , 2017, Journal of the Neurological Sciences.

[3]  B. Thomas,et al.  Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma? , 2017, American Journal of Neuroradiology.

[4]  J. Deverdun,et al.  Brain magnetic resonance imaging helps to differentiate atypical multiple sclerosis with cavitary lesions and vanishing white matter disease , 2016, European journal of neurology.

[5]  S. Park,et al.  Successful Publication of Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy , 2016, Korean journal of radiology.

[6]  Sang Hyun Choi,et al.  Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part I. General Guidance and Tips , 2015, Korean journal of radiology.

[7]  Sang Hyun Choi,et al.  Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part II. Statistical Methods of Meta-Analysis , 2015, Korean journal of radiology.

[8]  B. Cohen,et al.  Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. , 2015, AJR. American journal of roentgenology.

[9]  Zhen-yu Ma,et al.  Cerebral tumefactive demyelinating lesions. , 2015, Oncology letters.

[10]  B. Brochet,et al.  Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study , 2015, Journal of Neurology.

[11]  Namkug Kim,et al.  Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions. , 2015, AJR. American journal of roentgenology.

[12]  B. Banwell,et al.  Clinical and Magnetic Resonance Imaging (MRI) Distinctions Between Tumefactive Demyelination and Brain Tumors in Children , 2014, Journal of child neurology.

[13]  C. Choi,et al.  Utility of Proton MR Spectroscopy for Differentiating Typical and Atypical Primary Central Nervous System Lymphomas from Tumefactive Demyelinating Lesions , 2014, American Journal of Neuroradiology.

[14]  Ching-Piao Tsai,et al.  Tumefactive Multiple Sclerosis in Taiwan , 2013, PloS one.

[15]  A. Achiron,et al.  Diffusion Tensor Imaging Analysis of Tumefactive Giant Brain Lesions in Multiple Sclerosis , 2013, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[16]  David H. Miller,et al.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis , 2013, Journal of Neurology.

[17]  J. Chataway,et al.  Tumefactive demyelination: an approach to diagnosis and management , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  A. Kurne,et al.  Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center. , 2013, Turkish neurosurgery.

[19]  Ben Vandermeer,et al.  Chapter 8: Meta-analysis of Test Performance When There is a “Gold Standard” , 2012, Journal of General Internal Medicine.

[20]  S. Ng,et al.  Differentiation of Tumefactive Demyelinating Lesions from High-Grade Gliomas with the Use of Diffusion Tensor Imaging , 2012, American Journal of Neuroradiology.

[21]  C. Boz,et al.  Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study , 2012, Multiple sclerosis.

[22]  B. Thomas,et al.  Conventional and advanced magnetic resonance imaging in tumefactive demyelination , 2011, Acta radiologica.

[23]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[24]  T. Taoka,et al.  Characteristic Neuroimaging in Patients with Tumefactive Demyelinating Lesions Exceeding 30 mm , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[25]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions : Explanation and Elaboration , 2009 .

[26]  K. Chang,et al.  Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. , 2009, Radiology.

[27]  M. Singh,et al.  Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy , 2009, Multiple sclerosis.

[28]  H. Lassmann The pathologic substrate of magnetic resonance alterations in multiple sclerosis. , 2008, Neuroimaging clinics of North America.

[29]  W. Brück,et al.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis , 2008, Brain : a journal of neurology.

[30]  F. Barkhof,et al.  MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain , 2007, Journal of Neurology.

[31]  Jonathan J Deeks,et al.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. , 2005, Journal of clinical epidemiology.

[32]  J. Smirniotopoulos,et al.  Tumefactive demyelinating lesions , 1996, Neuroradiology.

[33]  C. Given,et al.  The MRI appearance of tumefactive demyelinating lesions. , 2004, AJR. American journal of roentgenology.

[34]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[35]  G. Johnson,et al.  Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. , 2001, AJNR. American journal of neuroradiology.

[36]  Y Ge,et al.  Enhancing patterns in multiple sclerosis: evolution and persistence. , 2001, AJNR. American journal of neuroradiology.

[37]  J. Masdeu,et al.  Open-ring imaging sign , 2000, Neurology.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  J. Kepes,et al.  Large focal tumor‐like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients , 1993, Annals of neurology.